These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36725884)

  • 1. 143D, a novel selective KRAS
    Xu LS; Zheng SX; Mei LH; Yang KX; Wang YF; Zhou Q; Kong XT; Zheng MY; Jiang HL; Xie CY
    Acta Pharmacol Sin; 2023 Jul; 44(7):1475-1486. PubMed ID: 36725884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The KRAS
    Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
    Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-1553: A novel KRAS
    Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
    Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The KRAS
    Briere DM; Li S; Calinisan A; Sudhakar N; Aranda R; Hargis L; Peng DH; Deng J; Engstrom LD; Hallin J; Gatto S; Fernandez-Banet J; Pavlicek A; Wong KK; Christensen JG; Olson P
    Mol Cancer Ther; 2021 Jun; 20(6):975-985. PubMed ID: 33722854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PI3Kα overcomes resistance to KRas
    Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
    Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
    Rosell R; Jantus-Lewintre E; Cao P; Cai X; Xing B; Ito M; Gomez-Vazquez JL; Marco-Jordán M; Calabuig-Fariñas S; Cardona AF; Codony-Servat J; Gonzalez J; València-Clua K; Aguilar A; Pedraz-Valdunciel C; Dantes Z; Jain A; Chandan S; Molina-Vila MA; Arrieta O; Ferrero M; Camps C; González-Cao M
    Cell Commun Signal; 2024 Jun; 22(1):324. PubMed ID: 38867255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS
    Lv Y; Yang Z; Chen Y; Ma X; Guo M; Zhang C; Jiang X; Wang C; Li Z; Tai Z; Wang X; Zhang S; Ma S; Qin C
    J Med Chem; 2024 Feb; 67(4):2487-2511. PubMed ID: 38316747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
    Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
    Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
    [No Abstract]   [Full Text] [Related]  

  • 9. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
    Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
    Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Acquired Resistance to KRAS
    Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
    Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Tu G; Liu Q; Qiu Y; Leung EL; Yao X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
    Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
    J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
    Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
    Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models.
    Nakayama A; Nagashima T; Nishizono Y; Kuramoto K; Mori K; Homboh K; Yuri M; Shimazaki M
    Br J Cancer; 2022 Mar; 126(5):744-753. PubMed ID: 34795410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRAS
    Cheng R; Lv X; Bu H; Xu Q; Wu J; Xie K; Tang J; Wang L; Zhuang J; Zhang Y; Zhang Y; Yan C; Lai Y
    Eur J Med Chem; 2022 Dec; 244():114808. PubMed ID: 36228411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.
    Imaizumi T; Shimada I; Satake Y; Yamaki S; Koike T; Nigawara T; Kaneko O; Amano Y; Mori K; Yamanaka Y; Nakayama A; Nishizono Y; Shimazaki M; Nagashima T; Kuramoto K
    Bioorg Med Chem; 2024 Jan; 98():117581. PubMed ID: 38176113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the Clinical Development Candidate
    Fell JB; Fischer JP; Baer BR; Blake JF; Bouhana K; Briere DM; Brown KD; Burgess LE; Burns AC; Burkard MR; Chiang H; Chicarelli MJ; Cook AW; Gaudino JJ; Hallin J; Hanson L; Hartley DP; Hicken EJ; Hingorani GP; Hinklin RJ; Mejia MJ; Olson P; Otten JN; Rhodes SP; Rodriguez ME; Savechenkov P; Smith DJ; Sudhakar N; Sullivan FX; Tang TP; Vigers GP; Wollenberg L; Christensen JG; Marx MA
    J Med Chem; 2020 Jul; 63(13):6679-6693. PubMed ID: 32250617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
    Misale S; Fatherree JP; Cortez E; Li C; Bilton S; Timonina D; Myers DT; Lee D; Gomez-Caraballo M; Greenberg M; Nangia V; Greninger P; Egan RK; McClanaghan J; Stein GT; Murchie E; Zarrinkar PP; Janes MR; Li LS; Liu Y; Hata AN; Benes CH
    Clin Cancer Res; 2019 Jan; 25(2):796-807. PubMed ID: 30327306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The path to the clinic: a comprehensive review on direct KRAS
    Kwan AK; Piazza GA; Keeton AB; Leite CA
    J Exp Clin Cancer Res; 2022 Jan; 41(1):27. PubMed ID: 35045886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.